北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学深圳医院  > 期刊论文
学科主题: 临床医学
题名:
A New PCR-Based Mass Spectrometry System for High-Risk HPV, Part II Clinical Trial
作者: Du, Hui1; Yi, Ji2; Wu, Ruifang1; Belinson, Suzanne E.3; Qu, Xinfeng3; Yang, Bin4; Wang, Chun1; Yi, Xin2; Belinson, Jerome L.1,5
关键词: Screening ; Cervical cancer ; Human papillomavirus ; HPV ; Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry system ; MALDI-TOF
刊名: AMERICAN JOURNAL OF CLINICAL PATHOLOGY
发表日期: 2011-12-01
DOI: 10.1309/AJCPJDAORUY4EYR6
卷: 136, 期:6, 页:920-923
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Pathology
研究领域[WOS]: Pathology
关键词[WOS]: CERVICAL-CANCER ; DETECT ; DNA ; PERFORMANCE ; CYTOLOGY
英文摘要:

This was a population-based clinical trial of a polymerase chain reaction based multiplex high-risk human papillomavirus (HR-HPV) assay using mass spectrometry (MassARRAY [Sequenom, San Diego, CA] matrix-assisted laser desorption/ionization time-of-flight mass spectrometry system [MALDI-TOF]). Participants were 10,000 women between the ages of 25 and 59 years in Guangdong Province, China (SHENCCAST II Study). All women collected a self-sample (tested with Cervista [Hologic, Marlborough, MA] and MALDI-TOF) followed by a clinician-collected cervical sample (for cytology, Hybrid Capture 2 [HC2; Qiagen, Gaithersburg, MD], Cervista, and MALDI-TOF). Patients with any abnormal result were asked to return for colposcopy and biopsies.

This analysis included the data for 8,556 women. The sensitivity values for cervical intraepithelial neoplasia (CIN) 3 or worse for a direct cervical sample were 97.9%, 95.1%, and 94.3 for HC2, Cervista, and MALDI-TOF, respectively (P >.05). The sensitivity for CIN 3 or worse for a self-collected sample tested with MALDI-TOF was also 94.3%, which was similar to a clinician-obtained endocervical sample assayed with the 3 HR-HPV assays. MALDI-TOF combined with a self-collected sample provides a highly sensitive, high-throughput, low-cost-per-case assay for mass screening.

语种: 英语
项目资助者: Shenzhen Female Doctors&prime ; Association, Shenzhen, China ; Hologic, Marlborough, MA ; Preventive Oncology International, Cleveland Heights, OH
WOS记录号: WOS:000297274500013
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/66944
Appears in Collections:北京大学深圳医院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Shenzhen Hosp, Shenzhen, Peoples R China
2.BGI, Shenzhen, Peoples R China
3.Prevent Oncol Int, Cleveland Hts, OH USA
4.Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA
5.Cleveland Clin, Womens Hlth Inst, Cleveland, OH 44106 USA

Recommended Citation:
Du, Hui,Yi, Ji,Wu, Ruifang,et al. A New PCR-Based Mass Spectrometry System for High-Risk HPV, Part II Clinical Trial[J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY,2011,136(6):920-923.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Du, Hui]'s Articles
[Yi, Ji]'s Articles
[Wu, Ruifang]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Du, Hui]‘s Articles
[Yi, Ji]‘s Articles
[Wu, Ruifang]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace